Shizuoka Prefecture

Kabushiki Kaisha Yakult Honsha

Pharmadesign, Inc.

Kumamoto Health Science University

Shinshu University

General Incorporated Association Pharma Valley Project Supporting Organization

Pharma IP General Incorporated Association

Shizuoka Prefectural University Corporation

Yasuto Akiyama

Osamu Takahashi

Naohisa Ogo

Akira Asai

Hitomi Shimizu

Akira Iizuka

Takeshi Masaki

Yoshiaki Masuda

Takane Yokotagawa

Ken Yamaguchi

Tadashi Okawara

Tadashi Ashizawa

Kenji Matsuno

Keiichi Hatakeyama

Ayumu Muroya

Shun-ichiro Taniguchi

Keiichi Ohshima

Tohru Mochizuki

Shun-Ichiro Taniguchi

Kouji Maruyama

Yuji Shimoda

Yoshinobu Ishikawa

Takeshi Nagashima

Kengo Inoue

An object is to produce a new anti-B7-H4 antibody having high specificity and affinity and provide a composition for treating cancer making use thereof. A monoclonal antibody that specifically binds to an extracellular domain protein of a human B7-H4 protein is newly produced and an 'anti-B7-H4 antibody-effector cell complex' in which the monoclonal antibody and an effector cell are bound in order to enhance the antibody-dependent cellular cytotoxicity of the monoclonal antibody or a bispecific antibody comprising an antigen recognition region of the monoclonal antibody and an effector cell antigen recognition region is further produced and used as a composition for treating cancer.

Anti-B7-H4 antibody

It is an object of the present invention to provide signal sequence information capable of secreting an antibody to the outside of cells in generation of the antibody by microorganisms of genus, and an antibody expression vector capable of secreting an antibody to the outside of cells by utilizing the signal sequence information. As a means for achieving the aforementioned object, there is prepared, which is transformed with a vector having inserted thereinto a DNA insert comprising the 5'-terminus of an antibody gene linked to the 3&#x2032;-terminus of a DNA encoding a signal peptide-linker conjugate having a linker linked to the C-terminus of a signal peptide consisting of an amino acid sequence shown in SEQ ID NO: 1.

Antibody gene expression-secretion system

Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; Rrepresents a hydrogen atom or the like; and &#x2014;X&#x2014;Y represents a diaryl group such as a biphenyl group). 

1,3,4-Oxadiazole-2-carboxamide compound

The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR; and Rto Rand Reach represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof. 

STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient

Growing community of inventors

Shizuoka, Japan

Yasuto Akiyama